Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ELCC 2025 Industry Satellite Symposia webcasts

ESMO-ELCC-2025-1000x1000

Watch the webcasts from our industry partners' Satellite Symposia.

28 Mar 2025

Johnson & Johnson: 
Transforming clinical practice in EGFR-mutant NSCLC

Coming soon

  • Welcome and introductions
    Nicolas Girard
  • Guiding treatment options for common EGFR-mutant NSCLC
    Raffaele Califano
  • Optimising management for patients with common EGFR mutations
    Vincent Sibaud
  • Discussion
  • Closing remarks
    Natasha Leighl
Pfizer: 
Promising new targets and ADCs in development for NSCLC

Watch session

  • Welcome and introduction
    David Planchard
  • Are we making progress? Updates on late-stage ADCs in NSCLC
    David Planchard
  • What’s next in NSCLC? New targets and ADC innovations
    Anna R. Minchom
  • Conclusions and panel discussion
    David Planchard, Anna R. Minchom
touchIME: 
Navigating the clinical impact of TROP2-targeting in NSCLC

Watch session

  • The emergence of TROP2 in NSCLC
    Marina C. Garassino
  • Clinical impact of targeting TROP2 in NSCLC
    Jarushka Naidoo
  • Clinical utility of TROP2 expression in NSCLC
    David Planchard
  • Managing ADC toxicities in NSCLC clinical practice
    Marina C. Garassino, Jarushka Naidoo, David Planchard
  • Future directions for TROP2 in NSCLC
    Marina C. Garassino

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.